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Objective: Decreased expression of inwardly rectifying potassium (Kir) channels in astrocytes and glioma cells may
contribute to impaired K+ buffering and increased propensity for seizures. Here, we evaluated the potential effect of
inflammatory molecules, such as interleukin-1β (IL-1β) on Kir4.1 mRNA and protein expression.
Methods: We investigated Kir4.1 (Kcnj10) and IL-1β mRNA expression in the temporal cortex in a rat model of
temporal lobe epilepsy 24 h and 1 week after induction of status epilepticus (SE), using real-time PCR and western
blot analysis. The U373 glioblastoma cell line and human fetal astrocytes were used to study the regulation of Kir4.1
expression in response to pro-inflammatory cytokines. Expression of Kir4.1 protein was also evaluated by means of
immunohistochemistry in surgical specimens of patients with astrocytic tumors (n = 64), comparing the expression
in tumor patients with (n = 38) and without epilepsy (n = 26).
Results: Twenty-four hours after onset of SE, Kir4.1 mRNA and protein were significantly down-regulated in
temporal cortex of epileptic rats. This decrease in expression was followed by a return to control level at 1 week
after SE. The transient downregulation of Kir4.1 corresponded to the time of prominent upregulation of IL-1β
mRNA. Expression of Kir4.1 mRNA and protein in glial cells in culture was downregulated after exposure to IL-1β.
Evaluation of Kir4.1 in tumor specimens showed a significantly lower Kir4.1 expression in the specimens of patients
with epilepsy compared to patients without epilepsy. This paralleled the increased presence of activated microglial
cells, as well as the increased expression of IL-1β and the cytoplasmic translocation of high mobility group box 1
(HMGB1).
Conclusions: Taken together, these findings indicate that alterations in expression of Kir4.1 occurring in
epilepsy-associated lesions are possibly influenced by the local inflammatory environment and in particular by the
inflammatory cytokine IL-1β.
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Astrocytes, the major glial cell type of the central ner-
vous system (CNS), are known to play a major role in
normal brain signaling and their dysfunction has been
shown to be critically involved in the pathogenesis of
several human CNS disorders, including epilepsy (for
reviews see [1,2]). One of the most important physiological* Correspondence: e.aronica@amc.uva.nl
†Equal contributors
1Department of (Neuro)Pathology, Academic Medical Center, University of
Amsterdam, Meibergdreef 9, Amsterdam, AZ 1105, The Netherlands
4Swammerdam Institute for Life Sciences, Center for Neuroscience, University
of Amsterdam, Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© 2012 Zurolo et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfunctions of astrocytes is their ability to control ionic
homeostasis, in particular the extracellular concentration of
potassium, which influences neuronal excitability. The in-
wardly rectifying potassium (Kir) channel 4.1 has been
identified as a key player among the potassium channels
expressed in astrocytes responsible for spatial buffering
[3,4]. Conditional knock-out of Kir4.1 has been shown to
lead to inhibition of potassium and glutamate uptake,
hyperexcitability, and seizures [5,6]. Mutations in the
human Kir4.1 gene, KCNJ10, are associated with epilepsy
[7] and a compromised glial potassium spatial buffering has
been suggested to underlie the epilepsy phenotype [8]. In
addition, alterations in expression, localization, andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in a number of neurological disorders, including
temporal lobe epilepsy (TLE) and malignant gliomas
(for review see [9]). In tissue specimens obtained
from patients with epilepsy, both electrophysiological
and molecular studies suggest that impaired potas-
sium buffering and enhanced seizure susceptibility
may result from reduced expression of Kir4.1 chan-
nels [10-14]. In the fluid percussion injury model in
rat, a chronic dysfunction of Kir channels (with de-
pletion of Kir4.1 immunoreactivity in processes of
neocortical astrocytes) in the epileptic focus has
been reported [15]. In case of astrocytic tumors,
which are often associated with seizure development,
mislocalization, and/or redistribution of Kir4.1, as
well as changes in the expression related to the ma-
lignancy grade, have been reported [9,16-18]. In
addition, attention has been focused on the role of
Kir channels as critical regulators of cell division,
suggesting that a loss of functional Kir4.1 may
underlie the re-entry of glial cells into the cell cycle
supporting gliosis and tumor development [9]. Al-
though these observations support an important role
for astrocytic Kir4.1, it remains still unclear whether
the changes in Kir4.1 expression represent the cause
or the consequence of epilepsy and the mechanism
underlying the regulation of the expression of Kir4.1
is still matter of discussion. It has been shown that
albumin uptake into astrocytes, mediated by trans-
forming growth factor (TGF)-β receptors, produces a
downregulation of Kir4.1 in these cells [19]. In
spinal cord injury, the downregulation of Kir4.1 has
been suggested to be dependent on the nuclear es-
trogen receptor signaling [20]. Moreover, recently,
Kir4.1 expression has been suggested to be influ-
enced by changes in the extracellular environment of
inflammatory cytokines, such as interleukin-1β (IL-1β)
[21]. Interestingly, increasing evidence supports the notion
that dysregulation of the astrocyte immune-inflammatory
function is a common factor predisposing or directly con-
tributing to the generation of seizures in epilepsy of various
etiologies [1,22,23].
Our major aim was to investigate the potential ef-
fect of inflammatory molecules, such as IL-1β on
Kir4.1 expression using both a glioblastoma cell line
and human astrocytes in culture.
The anti-inflammatory effects of the antiepileptic drug
(AED) levetiracetam reported recently in vivo and in vitro
[24,25], prompted us to evaluate the effect of this AED on
Kir4.1 expression in cultures exposed to IL-1β. In addition,
in order to detect changes in Kir4.1 expression and/or
localization in tumor astrocytes and their relationship to
IL-1β expression and to the tumor epileptogenicity, astro-
cytic tumors with and without epilepsy were studied.Materials and methods
Experimental animals
Adult male Sprague–Dawley rats (Harlan CPB laborator-
ies, Zeist, The Netherlands) weighing 300 to 500 g were
used in this study which was approved by the University
Animal Welfare committee. The rats were housed indi-
vidually in a controlled environment (21 ± 1°C; humidity
60%; lights on 08:00 to 20:00; food and water available
ad libitum).
Electrode implantation and seizure induction
In order to record hippocampal EEG, a pair of insulated
stainless steel electrodes (70 μm wire diameter, tips were
80 μm apart) were implanted into the left dentate gyrus
(DG) under electrophysiological control as previously
described [26]. A pair of stimulation electrodes was
implanted in the angular bundle. Rats underwent tetanic
stimulation (50 Hz) of the hippocampus in the form of a
succession of trains of pulses every 13 s. Each train had
a duration of 10 s and consisted of biphasic pulses (pulse
duration 0.5 ms, maximal intensity 500 μA). Stimulation
was stopped when the rats displayed sustained forelimb
clonus and salivation for minutes, which usually occurred
within 1 h. However, stimulation never lasted longer than
90 min. Differential EEG signals were amplified (10×) via a
FET transistor that connected the headset to a differential
amplifier (20×; CyberAmp, Axon Instruments, Burlingame,
CA, USA), filtered (1 to 60 Hz), and digitized by a com-
puter. A seizure detection program (Harmonie, Stellate Sys-
tems, Montreal, Canada) sampled the incoming signal at a
frequency of 200 Hz per channel. EEG recordings were
monitored also visually and screened for seizure activity.
Behavior was observed during electrical stimulation and
several hours thereafter. Immediately after termination of
the stimulation, periodic epileptiform discharges PEDs) oc-
curred at a frequency of 1 to 2 Hz and they were accom-
panied by behavioral and EEG seizures (status epilepticus).
Rat tissue preparation for RNA isolation and western blot
analysis
After decapitation, the brain was removed and dissected
and the temporal cortex was cut out of the slices under
a dissection microscope. Rats were decapitated in the
acute phase (1 day after SE, n = 6) and in the latent
period (1 week after SE, n = 6; the rats in this group did
not exhibit spontaneous seizures). Age-matched rats that
were implanted but not stimulated except for field po-
tential recordings were also included (n = 6). All material
was frozen on dry ice and stored at −80°C until use. For
western blot analysis frozen samples of control (n = 5),
1 day post SE (n = 5), and 1 week after SE (n = 5) were
homogenized in lysis buffer (as described below) and
protein content was determined using the bicinchoninic
acid method [27].
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For experiments with astrocytes-enriched human cul-
tures, fetal brain tissue (15 to 23 weeks of gestation) was
obtained from spontaneous or medically-induced abor-
tions with appropriate maternal written consent for
brain autopsy. Resected tissue samples were collected in
Dulbecco’s modified Eagle’s medium (DMEM)/HAM
F10 (1:1) medium (Gibco, Life Technologies), supple-
mented with 50 units/mL penicillin and 50 μg/mL
streptomycin and 10% fetal calf serum (FCS). Cell isola-
tion was performed as previously described [28,29].
Briefly, after removal of meninges and blood vessels, tis-
sue was minced and dissociated by incubation at 37°C
for 20 min in a Hank’s balanced salt solution containing
2.5 mg/mL trypsin (Sigma, St. Louis, MO, USA) and
0.1 mg/mL bovine pancreatic Dnase I (Boehringer
Mannheim, Germany). Tissue was triturated and washed
with DMEM/HAM F10 medium, supplemented with 50
units/mL penicillin and 50 μg/mL streptomycin and 10%
FCS. Cell suspension (containing approximately 0.5 g
wet weight tissue/10 mL culture medium) was passed
through a 70 μm cell sieve (Becton Dickinson, USA) and
plated into 25 cm2 flasks (Falcon, Lincoln Park, NJ,
USA) and maintained in a 5% CO2 incubator at 37°C.
After 48 h the culture medium was replaced by fresh
medium and cultures were subsequently fed twice a
week. Cultures reached confluence after 2 to 3 weeks.
Secondary astrocyte cultures were established by trypsi-
nizing confluent cultures and sub-plating into 6- and 24-
well plates (Costar; 0.5 × 106 cell/well in a 6-well plate
for western blot analysis or 0.1 × 106 cell/well in a 24-
well plate for RNA isolation and PCR) and simultan-
eously into 12 mm coverslips (Sigma) in 24-well plates
(Costar; 2 × 104 cell/well; for immunocytochemistry).
More than 98% of the cells in primary culture, as well as
in the successive 12 passages, were strongly immunor-
eactive for the astrocytic marker GFAP and S100β. In
the present study astrocytes were used for immunocyto-
chemical analyses at passage 3 to 4. The astrocytoma cell
line U373 was obtained from the American Type Culture
Collection (Rockville, MD, USA); cells were cultured in
DMEM/HAM F10 (1:1) supplemented with 50 units/mL
penicillin, 50 μg /mL streptomycin and 10% FCS.
Treatment of cell cultures
Human recombinant (r)IL-1β (Peprotech, NJ, USA; 10 ng/
mL) was applied and maintained for 24 h before harvest-
ing the cells for RNA isolation, western blot analysis or for
immunocytochemistry. In some experiments different
time periods of IL-1β exposure (ranging from 10 min to
48 h) were used and rIL-6 (10 ng/mL; Strathmann Biotec
A.G., Hamburg, Germany), tumor necrosis factor α
(TNFα; 1 ng/mL; Peprotech, NJ, USA) and high mobility
group box 1 (HMGB1; 40nM; HMGBiotech S.r.l., Milan,Italy) alone or together with IL-1β were applied and main-
tained in the medium for 24 h before harvesting the cells
for RNA isolation. Human IL-1receptor antagonist (IL-
1Ra; 1 μg/mL; Peprotech, NJ, USA) was used to neutralize
IL-1β activity (applied 1 h before IL-1β). As previously
shown [29] the viability of human astrocytes in culture
was not influenced by the treatments. In other experi-
ments, cells exposed to IL-1β (for 24 h) were extensively
washed with phosphate-buffered saline (PBS) and incu-
bated up to 48 h in culture medium, before harvesting
them for western blot analysis.Preparation of cellular extracts
Cells were harvested at 24 h after treatment and washed
twice with cold PBS. The samples were homogenized in
lysis buffer containing 10 mM Tris (pH 8.0), 150 mM
NaCl, 10% glycerol, 1% NP-40, Na orthovanadate
(10.4 mg/mL), 5 mM EDTA (pH 8.0), 5 mM NaF and pro-
tease inhibitor cocktail (Boehringer Mannheim, Germany)
by incubating on ice for 15 min. The homogenates were
centrifuged at 14,000 rpm for 10 min and the supernatant
was used for further analysis.Western blot analysis
Western blot analysis was performed, as previously
described [30]. For electrophoresis, equal amounts of
proteins (15 to 20 μg/lane) were separated on a 10% so-
dium dodecylsulfate-polyacrylamide gel electrophoretic
(SDS-PAGE) gel. Separated proteins were transferred to
nitrocellulose paper for 90 min at 100 V, using a wet
electroblotting system (BioRad, Hercules, CA, USA).
Membranes were blocked for 1 h in 5% non-fat dry milk
in Tris-buffered saline-Tween (TBST) (20 mM Tris,
150 mM NaCl, 0.1% Tween 20, pH 7.5). The blots were
incubated overnight with the primary antibody (Kir4.1
rabbit polyclonal antibody 1:1,000 in 5% milk solution,
Alomone Labs, Jerusalem, Israel).
After several washes in TBST, the membranes were
incubated in TBST/5% non-fat dry milk, containing the
goat anti-rabbit or rabbit anti-mouse coupled to horse
radish peroxidase (1:2,500; Dako, Denmark) for 1 h.
After washes in TBST, immunoreactivity was visualized
using ECL PLUS western blotting detection reagent (GE
Healthcare Europe, Diegen, Belgium). Expression of β-
actin (monoclonal mouse, Sigma, St. Louis, MO,
1:50,000) or β-tubulin (monoclonal mouse, Sigma, St
Louis, MO, 1:30,000) were used as loading control. For
the quantification of the blots the band intensities were
measured densitometrically using the Scion Image for
Windows (beta 4.02) image-analysis software. A ratio of
the band intensity of the protein of interest to that of
the reference protein was used to normalize expression.
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(qPCR)
For RNA isolation, 800 μL Trizol LS Reagent (Invitro-
gen, Carlsbad, CA, USA) was added to 0.1 to 0.5 × 106
cells. After addition of 200 μg glycogen and 200 μL
chloroform, the aqueous phase was isolated using Phase
Lock tubes (5 Prime GmBH, Hamburg, Germany). RNA
was precipitated with isopropyl alcohol, washed with
75% ethanol and dissolved in water. The concentration
and purity of RNA were determined at 260/280 nm
using a nanodrop spectrophotometer (Thermo Fisher
Scientific, Wilmington, DE, USA).
Five micrograms of total RNA were reverse-
transcribed into cDNA using oligo dT primers. Five
nmol oligo dT primers were annealed to 5 μg total RNA
in a total volume of 25 μL, by incubation at 72°C for
10 min, and cooled to 4°C. Reverse transcription was
performed by the addition of 25 μL RT-mix, containing:
First Strand Buffer (Invitrogen-Life Technologies), 2 mM
dNTPs (Pharmacia, Germany), 30 U RNAse inhibitor
(Roche Applied Science, Indianapolis, IN, USA) and 400
U M-MLV reverse transcriptase (Invitrogen - Life Tech-
nologies, The Netherlands). The total reaction mix (50
μL) was incubated at 37°C for 60 min, heated to 95°C
for 10 min and stored at −20°C until use.
PCR primers (Eurogentec, Belgium) were designed
using the Universal Probe Library of Roche (https://
www.roche-applied-science.com) on the basis of the
reported mRNA sequences. For the rat we used: Kir4.1/
Kcnj10 (forward: gtgacaggcaaactgcttca and reverse: gggc
tatcagaggctgtgtc); IL-1β (forward: aaaaatgcctcgtgctgtct;
reverse: tcgttgcttgtctctccttg); and GAPDH (forward:
atgactctacccacggcaag; reverse: tactcagcaccagcatcacc). For
the human cell cultures we used: Kir4.1 (forward:
acctcggacccaagatgac; reverse: gtatccctgggcccattag); IL-1β
(forward: gcatccagctacgaatctcc reverse: gaaccagcatcttcct
cagc); elongation factor 1-alpha (EF1α; forward: atc
cacctttgggtcgcttt; reverse: ccgcaactgtctgtctcatatcac); and
hypoxanthine phosphoribosyl transferase (HPRT; for-
ward: tggcgtcgtcgtgattagtgatg; reverse: tgtaatccagcaggt
cagca). For each PCR, a mastermix was prepared on ice,
containing per sample: 1 μL cDNA, 2.5 μL of FastStart
Reaction Mix SYBR Green I (Roche Applied Science, In-
dianapolis, IN, USA), 0.4 μM of both reverse and for-
ward primers. The final volume was adjusted to 5 μL
with H2O (PCR grade). The LightCycler
W 480 Real-Time
PCR System (Roche-applied-science) was used with a
384-multiwell plate format. The cycling conditions were
carried out as follows: initial denaturation at 95°C for
5 min, followed by 45 cycles of denaturation at 95°C for
15 s, annealing at 55 to 60°C for 5 s and extension at
72°C for 10 s. The fluorescent product was measured by
a single acquisition mode at 72°C after each cycle. For
distinguishing specific from non-specific products andprimer dimers, a melting curve was obtained after amp-
lification by holding the temperature at 65°C for 15 s fol-
lowed by a gradual increase in temperature to 95°C at a
rate of 2.5°C s-1, with the signal acquisition mode set to
continuous. Quantification of data was performed using
the computer program LinReg PCR in which linear re-
gression on the Log(fluorescence) per cycle number data
is applied to determine the amplification efficiency per
sample [31]. The starting concentration of each specific
product was divided by the starting concentration of
reference genes (GAPDH, for rat material; HPRT and
EF1a for the cell cultures) and this ratio was compared
between patient/control groups.
Human material
The human cases included in this study were obtained
from the files of the departments of neuropathology
of the Academic Medical Center (AMC, University of
Amsterdam) and the VU University Medical Center
(VUMC), both situated in Amsterdam and both ter-
tiary referral centers for brain tumor patients in the
Netherlands. We examined immunocytochemically 73
surgical specimens of brain tumor patients with astro-
cytic tumors (6 WHO grade II astrocytoma; 12 WHO
grade III astrocytoma; 55 glioblastoma multiforme,
GBM; Table 1). Normal-appearing control cortex/
white matter was obtained at autopsy from eight adult
control patients without a history of seizures or other
neurological diseases. All autopsies were performed
within 12 h after death. Cortical samples (cortex/
white matter adjacent to the lesion with reactive
changes, such as astrogliosis, but not tumor cells) of
five patients with non-glial brain tumors (two men-
ingiomas, one metastasis of carcinoma, and one
lymphoma) and without refractory epilepsy were also
analyzed (control cortex/surgical, Table 1). Frozen tis-
sue from histologically normal cortex (n = 2) and GBM
(n = 4) samples was used for western blot analysis
and total RNA prepared from normal cortex (n = 6)
and GBM (n = 8; four with epilepsy and four without
epilepsy) was used for qPCR.
A chart review was conducted of all patients. Epilepsy
was defined as the experience of one or more seizures
and data regarding seizure frequency and seizure type
were obtained from patient histories. We collected
additional data including age, gender, tumor location,
and epilepsy duration. Informed consent was obtained
for the use of brain tissue and for access to medical
records for research purposes. Tissue was obtained and
used in a manner compliant with the Declaration of Hel-
sinki. Two neuropathologists reviewed all cases inde-
pendently and the diagnosis was confirmed according to
the revised WHO classification of tumors of the central
nervous system [32].
Table 1 Clinical and histopathological features
A II(n = 6) A III(n = 12) GBM(n = 55) Control cortex/autopsy (n = 8) Control cortex/surgical (n = 5)
Gender (m/f) 4/2 7/5 33/22 5/3 3/2
Age (years)a 34 (22–43) 44.7 (33–51) 56.5 (26–76) 50 (30–72) 54 (43–75)
Location -
Frontal 5 3 18 4 2
Temporal 1 3 15 1 -
Parietal - - 4 5 2
Occipital - 1 3 1 -
Thalamus - - 1 - -
Parietooccipital - 2 3 - -
Temporoccipital - 2 1 - 1
Temporoparietal - - 1 - -
Frontotemporal - 1 3 - -
Frontoparietal - - 1 - -
Epilepsy 6 7 29 - -
Duration epilepsy (months)a 6 (4–11) 4.8 (1–9) 6.5 (1–12) - -
aMean (range); A II, Astrocytoma WHO grade II; A III, Astrocytoma WHO grade III; GBM, Glioblastoma multiforme.
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Tissue was fixed in 10% buffered formalin and embed-
ded in paraffin. Paraffin-embedded tissue was sectioned
at 5 μm, mounted on precoated glass slides (Star Frost,
Waldemar Knittel GmbH, Brunschweig, Germany) and
used for immunohistochemical staining as described below.
Antibodies
Antibodies specific for glial fibrillary acidic protein (GFAP;
polyclonal rabbit, DAKO, Glostrup, Denmark; 1:4,000;
monoclonal mouse; DAKO; 1:50), vimentin (mouse clone
V9; DAKO; 1:1,000), neuronal nuclear protein (NeuN;
mouse clone MAB377; Chemicon, Temecula, CA, USA;
1:2,000), synaptophysin (mouse clone Sy38; DAKO; 1:200;
rabbit anti-synaptophysin; DAKO; 1:200), Ki67 (mouse
clone MIB-1; DAKO; 1:200), (HLA)-DP, DQ, DR (HLA-
DR; mouse clone CR3/43; DAKO, Glostrup, Denmark,
1:400), MAP2 (mouse clone HM2; Sigma 1:100) and p53
(Clone DO-7 + BP53-12; Neomarkers; 1:2,000), were used
in the routine immunohistochemical analysis of glial
tumors. For the detection of Kir4.1, we used a polyclonal
rabbit antibody (Alomone Labs, Ltd, Jerusalem, Israel;
1:100); for the detection of IL-1β a polyclonal goat anti-
body (sc-1250, Santa Cruz Bio., CA, USA; 1:70; [33]) and
for the detection of HMGB, we used a polyclonal rabbit
antibody (Pharmingen, San Diego, CA, USA; 1:100; [34];
Abcam Cambridge, UK).
Immunohistochemistry
Paraffin-embedded sections were deparaffinized, re-
hydrated, and incubated for 20 min in 0.3% H2O2diluted in methanol to quench the endogenous per-
oxidase activity. Antigen retrieval was performed by
incubation for 10 min at 121°C in citrate buffer (0.01 M,
pH 6.0), sections were washed with phosphate-
buffered saline (PBS) and incubated for 30 min in
10% normal goat serum (Harlan Sera-Lab, Loughborough,
Leicestershire, UK).
Coverslips with adherent cells (U373 or fetal astro-
cytes) were rinsed in PBS (pH 7.4) and fixed for
15 min in 4% paraformaldehyde in PBS. After rins-
ing, cultures were incubated in PBS containing 10%
normal goat serum for 15 min prior to the incuba-
tion with the primary antibodies.
Sections were incubated with the primary antibodies
overnight at 4°C. Hereafter, sections were washed in
PBS and the ready-for-use Powervision peroxidase
system (Immunologic, Duiven, The Netherlands) and
3,3’-diaminobenzidine (DAB; Sigma) was used to de-
velop the color reaction. Sections were counterstained
with hematoxylin, dehydrated and coverslipped. Sec-
tions incubated without the primary antibody were es-
sentially blank. To test the specificity of the antibody,
western blot analysis of the total homogenates of
human histologically normal cortex (n = 2) and GBM
(n = 4) samples was performed, as described above.
The number of available frozen tumor samples from
patient with and without epilepsy was too small to
perform meaningful statistical comparisons in sub-
groups and to assess whether Kir4.1 expression is
more directly dependent on presence or absence of
seizures or tumor type by western blot analysis.
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Semi-quantitative evaluation of immunoreactivity (IR) in
tumor specimens was performed as previously [33,35]
using a using a semi-quantitative scale ranging from 0 to
3 (0: -, no; 1: +/−, weak; 2: +, moderate; 3: ++, strong
IR). Two representative sections per case were stained
and assessed with the Kir4.1 and IL-1β antibodies. The
intensity score represents the predominant staining in-
tensity found in each specimen as averaged from the
selected fields and the different sections per group. The
evaluation of the IR in tumor specimens was performed
in the center of the lesion, the infiltration zone was dis-
regarded. The sections were evaluated by two independent
observers blind to clinical data. In case of disagreement in-
dependent reevaluation was performed by both observers
to define the final score. The approximate proportion of
cells showing IR (0, <1%; 1, single to 25%; 2, 26% to 50%; 3,
51% to 75%; and 4, >75%) was also scored to give informa-
tion about the relative number (‘frequency’ score) of posi-
tive cells tumor specimens. As proposed before [36,37], the
product of these two values (intensity and frequency scores)
was taken to give the overall score (immunoreactivity total
score; IR score), shown in Tables 2 and 3. We also evalu-
ated the IR score of HLA-DR (markers of microglia activa-
tion) in tumor tissue of patients with or without epilepsy
and quantitative analysis was performed for HMGB1 in
these two patient groups, as previously described [34].
Briefly, three representative adjacent non-overlapping fields
of the areas of interest (A II, A III, and GBM) were cap-
tured (magnification 40×) and digitized (Leica DM5000B).
We counted the total number of astroglial/tumor cells and
those showing nuclear or extra-nuclear HMGB1 staining.
In cell cultures (U373 and fetal astrocytes) quantitative
analysis was carried out for the number of Kir4.1 immu-
noreactive cells. All cells were counted systematically at
high magnification (×40 objective; using an ocular grid
and counting 1,000 cells from two separate experiments)
as positive IR (including strong or intermediate intensity
of labeling) or negative. The percentage of labeled Kir4.1
was calculated based on the total number of cells.
Statistical analysis
Statistical analysis was performed with SPSS 15.0 and
PrismW (Graph Pad Software, Inc.) software for Win-
dows. To assess differences between groups, a non-Table 2 Kir4.1 and IL-1β immunoreactivity in astrocytic tumo
IR score A II(n = 6) A III(n = 12) GBM (n = 55 )
Kir4.1 3.6 ± 0.85* 7.18 ± 0.41 5.5 ± 0.30
IL-1β 2.46 ± 0.67* 3.9 ± 0.9* 3.75 ± 0.45*
HLA-DR 5.4 ± 0.77* 5.7 ± 0.80* 5.83 ± 0.35*
A II, Astrocytoma WHO grade II; A III, Astrocytoma WHO grade III; GBM, Glioblastom
Values represent the average immunoreactive score (IR) ± SEM. *P <0.05 (compared
Kir4.1 score for AII (P <0.05).parametric Kruskal-Wallis test was performed, followed
by the Mann–Whitney U test. Correlations between
Kir4.1 immunostaining and different variables (histo-
pathological diagnosis, epilepsy, the use of levetiracetam
and IL-1β immunoreactivity) were assessed with the
Mann–Whitney U test and the Spearman’s rank correl-
ation test. The value of P <0.05 was defined as statisti-
cally significant. Multiple testing was corrected by the
Bonferroni correction.
Results
Kir4.1 and IL-1β expression in rat temporal cortex after
induction of SE
To determine the temporal-spatial expression of Kir4.1
expression we performed qPCR in tissue samples of con-
trol rats and rats that were sacrificed at different time
points after SE (1 day and 1 week post SE). Kir4.1 ex-
pression significantly decreased at 24 h post SE and
returned toward control levels at 1 week after the onset
of SE (Figure 1A). Western blot analysis of total homo-
genates of rat temporal cortex revealed a band at mo-
lecular weight of approximately 40 kDa which showed a
significant decrease at 24 h post SE as compare to con-
trols (Figure 1C, D). The transient prominent decrease
of Kir4.1 mRNA expression following SE prompted us
to evaluate whether this decrease might be related to an
increased level of cytokines, such as IL-1β. Prominent
IL-1β upregulation was indeed observed 24 h post SE
(Figure 1B).
Regulation of Kir4.1 expression by IL-1β in human glial
cells in culture
To address the question of whether IL-1β was involved
in the modulation of Kir4.1 expression we used both
human fetal astrocytes and the U373 glioblastoma cell
line in culture. qPCR demonstrated that exposure to IL-
1 β consistently decreased Kir4.1 expression in both cell
types (Figure 2A and B). The effect of IL-1β was blocked
by the IL-1Ra, a naturally occurring antagonist of the
IL-1β receptor ([38]; Figure 2C). IL-1β significantly
decreased Kir4.1 mRNA levels already 30 min after ex-
posure to IL-1β (not shown) and its effect was maximal
at 24 h. The downregulation of Kir4.1 mRNA could be
partially reverted when IL-1β was removed and cultures
were incubated for 48 h in culture medium (Kir4.1rs
Control cortex/autopsy (n = 8) Control cortex/surgical (n = 5)
7.13 ± 0.36 7.03 ± 0.26
0 0.02 ± 0.02
0.04 ± 0.02 0.03 ± 0.02
a multiforme.
to control cortex, both autopsy and surgical samples). Kir4.1 IR score for AIII >
Table 3 Kir4.1 and IL-1β immunoreactivity in patients with/without epilepsy and with/without levetiracetam use
IR score With epilepsy (n = 42) Without epilepsy (n = 31) With levetiracetam (n = 14 ) Without levetiracetam (n = 28)
Kir4.1 4.9 ± 0.36* 6.5 ± 0.37 6.8 ± 0.62** 4.5 ± 0.37
IL-1β 5.5 ± 0.49* 1.3 ± 0.17 3.9 ± 1.14** 6.3 ± 0.46
HLA-DR 5.8 ± 0.31* 3.6 ± 0.36 4.28 ± 0.15 5.2 ± 0.40
Values represent the mean immunoreactive score (IR) ± SEM. *P <0.05: significant difference compared to patients without epilepsy; **P <0.05: significant
difference compared to patients without levetiracetam use.
Zurolo et al. Journal of Neuroinflammation 2012, 9:280 Page 7 of 17
http://www.jneuroinflammation.com/content/9/1/280expression (relative to control of 100%): 24 h IL-1β:
13.8% ± 2.0; 48 h after washout: 51.3% ± 2.7). In contrast,
under our culture conditions we did not observe signifi-
cant changes in the expression levels of Kir4.1 after ex-
posure to IL-6 (10 ng/mL), TNFα (1 ng/mL), or HMGB1
(40nM); cytokine treatments, including IL-1β, did not
influence the expression of Kir2.1, 2.3, and 3.1 mRNA
(not shown).
The recently described anti-inflammatory property of
the AED levetiracetam [24,25] prompted us to evaluate
its effect on IL-1β–induced Kir4.1 downregulation. Ex-
posure to levetiracetam did not affect IL-1β induced
Kir4.1 downregulation. However levetiracetam treatment
(for 24 h) significantly increased Kir4.1 mRNA com-
pared to untreated cells (Figure 2C). A similar effect was
observed 48 h after exposure to levetiracetam (not
shown).
Western blot analysis confirmed the downregulation
of Kir4.1 induced by IL-1β in U373 cells (Figure 2D) andFigure 1 Kir4.1 and IL-1β expression in rat temporal cortex after statu
levels of Kir4.1 (A) and IL-1β (B) in the temporal cortex of control rats (n = 6
represent the target gene expression normalized to the reference genes. T
Western blot analysis of Kir4.1. (C) Representative immunoblot of total hom
1 week) rats. (D) Densitometric analysis: values (optical density units, O.D.) a
SE, n = 5), relative to the optical density of β-tubulin; *P <0.05, compared tofetal astrocytes (Figure 2E) at the protein level. No sig-
nificant differences (at 24 h) in Kir4.1 protein levels were
detected in either cell culture after treatment with leve-
tiracetam (in the presence or absence of IL-1β; not
shown).
In both astrocytes-enriched human cell cultures and
glioma cells incubated with IL-1β, immunocytochemistry
demonstrated a lower percentage of Kir4.1-labeled cells
as compared to controls (Figure 3A-F). In U373 cells (but
not in fetal astrocytes), we also observed nuclear IR
(Figure 3A and B) in addition to cytoplasmic Kir4.1 IR.
Kir4.1 and IL-1β expression in human astrocytic
tumors
Patients
Table 1 summarizes the clinical and histopathological
characteristics of the patients and control cases. Thirty-
eight of the seventy-three tumor patients had epilepsy.s epilepticus (SE). (A, B) Quantitative real-time PCR. mRNA expression
; Con), rats at 1 week (n = 6), and 3 months (n = 6) after SE. Data
he error bars represent SEM and * represents a P value <0.05. (C, D)
ogenates from temporal cortex of controls and post SE (24 h and
re mean ± SEM, (control, n = 5; 24 h post SE, n = 5; and 1 week post
controls.
Figure 2 Kir4.1 expression in U373 glioblastoma cell line and in cultured human astrocytes after exposure to IL-1β. (A-C) Quantitative
real-time PCR. Expression levels of Kir4.1 mRNA 24 h after exposure to IL-1β (10 ng/mL) in U373 glioblastoma cell line (A) and in cultured human
astrocytes (B). (C) Expression levels of Kir4.1mRNA 24 h after exposure to IL-1β in U373 cell line in the presence or absence of the IL-1 β receptor
antagonist (IL-1Ra; 1 μg/mL) or levetiracetam (LEV; 10 μg/mL). Data are expressed relative to the levels observed in unstimulated cells (untreated
controls, Con) and are mean ± SEM from two separate experiments performed in triplicate (*P <0.05; ***P <0.0001 compared to control). (D, E).
Western blot analysis of Kir4.1. Representative immunoblot of total homogenates from U373 glioblastoma cell line (D) and from human fetal
astrocytes (E) untreated and treated for 24 h with 10 ng/mL IL-1β, in the presence or absence of the IL-1 β receptor antagonist (IL-1Ra; 1 μg/mL).
Densitometric analysis: values (optical density units, O.D.) are mean ± SEM, relative to the optical density of β-actin; *P <0.05, compared
to controls.
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seizures, followed by simple partial seizures. All 42
patients with epilepsy used antiepileptic drugs, 14 of
them used levetiracetam before operation.
Kir4.1 immunoreactivity
In control tissue we did not detect obvious differences in
the distribution of Kir4.1 between surgical and autopsy
cortical specimens. Kir4.1 IR was detected around blood
vessels (Figure 4A) as previously reported [16,17] and
occasionally in the cytoplasm of astroglial cells. Astrocy-
toma WHO grade II and III, as well as GBM displayed
mainly cytoplasmic staining in tumor cells (Figures 4B-F).
The expression at perivascular endfeet membranes was less
prominent and occasionally nuclear expression was
observed in astrocytoma grade III and GBM (not shown).
The IR score was significantly lower in astrocytoma
grade II compared to control cortex, as well as astrocy-
toma grade III (Table 2). GBM showed variable Kir4.1
expression and the IR score was not significantly differentcompared to the other tumor subtypes (Table 2; Figure 4E
and F). The variable Kir4.1 expression in GBM is also
reflected by western blot analysis of total homogenates
(Figure 4G). However, in this retrospective study, the num-
ber of frozen specimens available was too small to perform
statistical comparisons in subgroups.
Kir4.1 expression and epilepsy
The expression and distribution of Kir4.1 IR was com-
pared in tumor tissue of patients with astrocytoma
WHO grade II, WHO grade III and GBM with or with-
out epilepsy. A significantly lower Kir 4.1 expression was
found in tumor tissue of patients with epilepsy
(Figure 4B, C, E; Table 3). qPCR demonstrated lower Kir
4.1 mRNA expression in GBM with epilepsy compared
to GBM without epilepsy (Figure 6A).
The number of astrocytomas grade II and grade III
with and without epilepsy was too small to perform
a meaningful statistical comparison between these
Figure 3 Kir4.1 (IR) in U373 glioblastoma cell line and in cultured human astrocytes after exposure to IL-1β. (A-D) representative
photomicrographs showing Kir4.1 IR in glioma cells (U373; A, B) and cultured human astrocytes (C, D), untreated (A and C; Con) and treated (B
and D) for 24 h with 10 ng/mL IL-1β; high magnifications are shown in the inserts; in U373 cells Kir4.1 was also detected in the nuclei of glial
cells (insert in A and B). Scale bar in A: A and B: 80 μm; C and D: 40 μm. (E and F): percentage of Kir4.1 positivity in glioma cells (U373; E) and
cultured human astrocytes (F) untreated and treated for 24 h with 10 ng/mL IL-1β. *P <0.05, compared to untreated controls (Con).
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4.1 expression is dependent on the presence of sei-
zures or tumor type.
IL-1β immunoreactivity
As previously reported [33], IL-1β was under detection
level in both surgical and autopsy cortical specimens of
healthy controls (Figure 5A). Expression of IL-1β was
detected in the different tumor subtypes in tumor cells
(Figure 5B to F). The IR score for each tumor and con-
trol tissue is summarized in Table 2. The IR score was
significantly higher in astrocytoma grade II, III, as well
as GBM compared to control cortex. No significant dif-
ferences were detected between tumor subtypes
(Table 2). Astrocytoma grade II, III, as well as GBM dis-
played also higher IR score for HLA-DR compared to
controls (Table 2).
IL-1β expression and epilepsy
A significantly higher IL-1β expression was observed in
tumor tissue of patients with epilepsy (Figure 5B, C, E;Table 3). qPCR demonstrated higher IL-1β mRNA ex-
pression in GBM with epilepsy compared to GBM with-
out epilepsy (Figure 6B). Tumor tissue of patients with
epilepsy displayed also a higher IR score for HLA-DR
compared to controls (Table 3; Figure 7A-D). We also
evaluated the cellular localization of HMGB1, a nuclear
protein that can also act as an extracellular signal of in-
flammation [39-41]. We observed increased cytoplasmic
translocation of HMGB1 IR in tumor tissue of patients
with epilepsy compared to patients without epilepsy
(Figure 7E-I).
The number of astrocytomas grade II and grade III
with and without epilepsy was too small to perform a
meaningful statistical comparison in these subgroups.
The Spearman’s rank correlation test was applied to
evaluate the relationship between Kir4.1 and IL-1β IR. A
weak but significant negative correlation was observed
between the Kir4.1 and the IL-1β IR score (r = −0.3663;
P <0.05). No significant correlations were found between
Kir4.1 or IL-1β IR and clinical variables such as age at
surgery, age at seizure onset, and duration of epilepsy.
Figure 4 Expression of Kir4.1 immunoreactivity (IR) in glial tumor from patients with and without epilepsy. (A) Control white matter
showing Kir4.1 IR in processes of perivascular astrocytes. (B) Astrocytoma grade II (A II); (C-F) Representative photomicrographs of Kir4.1 IR in
astrocytoma grade III (A III; C and D) and glioblastoma multiforme (GBM; E and F) with (C and E) and without epilepsy (D and F); inserts: high
magnifications, showing cytoplasmic staining, with weak IR in epilepsy-associated tumors. Sections were counterstained with hematoxylin. Scale
bars: A: 40 μm; B-F: 160 μm. (F) Representative immunoblot of total homogenates from control cortex and GBM (with and without epilepsy) that
revealed a band at a molecular weight of approximately 40 kDa.
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The expression of Kir4.1 was evaluated in relation to
AED regimens, in particular to levetiracetam treatment
in patients with epilepsy. A significantly higher Kir4.1 IR
was observed in the patients treated with levetiracetam
compared to the patients who were not treated with this
AED (Table 3; Figure 8A-B). In contrast a lower expres-
sion of IL-1β (Table 3; Figure 8C-D) was observed in
levetiracetam-treated patients, whereas no differences
were observed for HLA-DR. In addition, the seizure free
interval was evaluated in levetiracetam-treated patients
to assess whether Kir4.1 expression was associated with
the presence of seizures and whether it was influencedby levetiracetam treatment. Of the 14 patients with epi-
lepsy who were treated with levetiracetam, six patients
were seizure free, six patients were not, and in one pa-
tient no data regarding seizure free interval was avail-
able. Kir4.1 expression was not correlated with seizure
free interval in levetiracetam-treated patients.
Discussion
The present study investigated the effect of the proin-
flammatory molecule IL-1β on the expression of Kir4.1,
a major K+- inward rectifying channel in astrocytes. In
addition, the expression pattern of Kir4.1 in primary
human glial tumors and its relationship to seizure
Figure 5 Expression of IL-1β immunoreactivity (IR) in glial tumors from patients with and without epilepsy. Representative
photomicrographs of IL-1β IR in control white matter (A) astrocytoma grade II (A II; B, with epilepsy), astrocytoma grade III (A III; A-D) and
glioblastoma multiforme (GBM; E and F) with (C and E) and without epilepsy (D and F); inserts: high magnifications, showing strong IR in
epilepsy-associated tumors. Sections were counterstained with hematoxylin. A-F: scale bar in A: 80 μm.
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observations were made: (1) in a rat model of TLE,
Kir4.1 mRNA and protein were significantly downregu-
lated in temporal cortex 24 h after onset of SE; this
downregulation corresponded to the time of prominent
upregulation of IL-1β; (2) IL-1β treatment reduced the
expression of Kir4.1 mRNA and protein in both a gliomaFigure 6 Kir4.1 and IL-1β mRNA expression in glioblastoma multiform
real-time PCR. Expression levels of Kir4.1 (A) and IL-1β (B) mRNA in GBM fro
expressed relative to the levels observed in control cortex (n = 5) and
without epilepsy).cell line and human astrocytes in culture; (3) Kir4.1 ex-
pression was lower in tumors with epilepsy compared to
tumors without epilepsy; (4) astrocytic tumors with epi-
lepsy displayed higher IL-1β IR compared to tumors
without epilepsy; (5) among the patients with epilepsy, a
significantly higher Kir4.1 IR was detected in the
patients treated with levetiracetam compared to thee (GBM) from patients with and without epilepsy. Quantitative
m patients with (n = 4) and without epilepsy (n = 4). Data are
are mean ± SEM (*P <0.05; compared to control and GBM
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nificance of these findings in relation to epileptogenesis
in astrocytic tumors is discussed below.
Downregulation of Kir4.1 mRNA after induction of SE
parallels the increased IL-1β expression
Impaired potassium buffering and enhanced seizure sus-
ceptibility have been suggested to result from reduced
expression of Kir4.1 channel in TLE ([10-14]; for review
see [2]). A previous micro-array study in the electrical
post-SE rat model showed that several potassium chan-
nel genes, including Kir channels were found to be
downregulated 24 h after induction of SE in the CA3 re-
gion of the hippocampus [42]. The present study con-
firmed the downregulation of Kir4.1 mRNA at 24 h post
SE in the temporal cortex. However, this decrease in ex-
pression (both mRNA and protein) recovered to control
levels after the latent period. A recent study suggests a
role for inflammatory cytokines, such as IL-1β, in the
regulation of the expression of Kir4.1 [21]. Interestingly,
experimentally-induced seizures in rodents trigger a
rapid upregulation of IL-1β and its receptor ([42,43]; for
review see [1,22]). IL-1β is among the best-characterized
early-response inflammatory cytokines and a key medi-
ator in the response of the brain to various forms of
CNS injury (for review see [44-46]. Accordingly, in the
present study, it was observed that IL-1β peaked in the
temporal cortex at 1 day after SE, which corresponds to
the time point of prominent reduction of Kir4.1 expres-
sion. A decrease of functional Kir channels has been
shown in other pathologies associated with activation of
the inflammatory response, including amyotrophic lat-
eral sclerosis and retinopathies ([47-49]; for review see
[9]). These observations suggest a role for IL-1β in the
regulation of Kir4.1 mRNA expression, which was fur-
ther investigated in vitro, using glial cells in culture.
IL-1β treatment downregulated Kir4.1 expression human
glial cells
Both U373 glioblastoma cells and human fetal astrocytes
in culture expressed Kir4.1 mRNA and protein. Im-
munocytochemical analysis showed cytoplasmic expres-
sion of Kir4.1 in human astrocytes, whereas both
cytoplasmic and nuclear expression was observed in gli-
oma cells. This is in agreement with previous studies
reporting a mislocalization of Kir channels to the nu-
cleus in glioma cell lines [18]. In the present study, IL-
1β treatment significantly decreased Kir4.1 mRNA levels
in both the U373 glioma cell line and fetal astrocytes in
culture. This effect (already observed at 30 min and
maximal at 24 h after exposure to IL-1β) could explain
the suppression of Kir4.1 mRNA expression observed
after seizure-induced release of this cytokine in vivo.
Under our experimental conditions, the effect ofdownregulation of Kir4.1 expression observed with IL1-
β treatment could not be reproduced by other pro-
inflammatory cytokines, such as IL-6 and TNFα or the
toll-like receptor 4 agonist, HMGB1. The observation
that IL-1Ra inhibited the effect of IL-1β on suppression
of Kir4.1 is consistent with the fact that IL-1β signals
through the type I IL-1β receptor. IL-1Ra is a naturally
occurring antagonist of the IL-1 receptor [38], which is
also regulated in response to different forms of CNS in-
sult (for review see [1,22,50]). Thus, it is tempting to
speculate that differential expression of inhibitory com-
ponents of the IL-1 system and in particular local
changes in the IL-1Ra/IL-1β ratio in brain, may critically
contribute to the regulation of Kir4.1 expression under
both physiological and pathological conditions. More-
over, the effect of IL-1β was partially reversible, with
Kir4.1 levels showing partial recovery 48 h after removal
of the cytokine. These observations suggest that the ex-
pression of Kir4.1 mRNA could be critically influenced
by local dynamic changes in the level of IL-1β in the
extracellular environment.
Recently, anti-inflammatory effects have been reported
for levetiracetam [24,25], an AED frequently used to
treat partial onset seizures, also in patients with brain
tumors ([35,51]). In particular, treatment with this AED
in neonatal rat astrocytes that were co-cultured with
activated microglia or treated with IL-1β has been
shown to restore impaired astrocyte membrane resting
potentials via modification of inward and outward recti-
fier currents [25]. These studies prompted us to evaluate
the effect of levetiracetam on IL-1β–induced Kir4.1
downregulation observed in human astrocytes and gli-
oma cells. Under our experimental condition, levetirace-
tam was not able to counteract the downregulatory
effect of IL-1β on Kir4.1 mRNA. It could be conceived
that this lack of effect of levetiracetam on IL-1β treated
cells is related to the dose of the cytokine used. Further
experiments using different IL-1β doses in combination
with levetiracetam are ongoing to address this issue.
However, in the absence of IL-1β, levetiracetam posi-
tively regulated Kir4.1 mRNA expression. The potential
effect of a chronic exposure to levetiracetam on IL-1β
and Kir4.1 protein expression was further investigated
in surgical astrocytic tumor specimens from patients
treated with levetiracetam.
Differential expression of Kir4.1 and IL-1β in astrocytic
tumors
Immunocytochemical analysis showed variable Kir4.1
expression in astrocytic tumors with mainly cytoplasmic
staining in tumor cells. Decrease of IR in glial processes
and particularly in perivascular astrocyte endfeet was
observed in both low- and high-grade gliomas, whereas
nuclear expression was detected only occasionally in
Figure 7 HLA-DR and HMGB1 expression in glial tumors from patients with and without epilepsy. (A-D) Representative photomicrographs
of HLA-DR IR in astrocytoma grade III (A III; A and B) and glioblastoma multiforme (GBM; C and D) with (A and C) and without (B and D)
epilepsy, showing immmunoreactive cells in epilepsy associated tumors. (E-H) Representative photomicrographs of HMGB1 IR in A III (E and F)
and GBM (G and H) with (E and G) and without (F and H) epilepsy, showing cytoplasmic staining (arrows in E and G) in epilepsy-associated
tumors. Sections were counterstained with hematoxylin. Scale bars: A-C: 160 μm; E-H: 60 μm. (I) Quantification bargrams of HMGB1-positive cells
in tumors with and without epilepsy. Extranuclear staining in epilepsy associated tumors: *P <0.05 vs. tumors without epilepsy.
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observed in glioma cell lines in culture ([18]; present
study) does not represent a consistent feature of human
primary glial tumor. Accordingly, nuclear localization
has not been reported in other studies analyzing the ex-
pression pattern of Kir4.1 in surgical specimens of both
low- and high-grade astrocytomas [16,17]. However, in
agreement with our observations, Warth and colleagues
[16] reported a redistribution of Kir4.1 in astrocytomas
(with reduced perivascular astrocyte endfeet), suggestinga compromised buffering capacity of glial tumor cells. In
our study the IR score was significantly lower in astrocy-
toma grade II compared to astrocytomas grade III,
whereas no differences were observed compared to
GBM. Tan and colleagues [17] investigated the expres-
sion of Kir4.1 mRNA and protein in astrocytic tumors
and reported higher expression in high-grade astrocytic
tumors compared to low-grade tumors. They suggested
that activation of Kir4.1 produced intracellular alkalini-
zation and could promote proliferation and inhibit
Figure 8 Expression of Kir4.1 and IL-1β immunoreactivity (IR) in glial tumors from patients with epilepsy, with and without
levetiracetam use. Representative photomicrographs of Kir4.1 (A and B; high magnifications in inserts) and IL-1β (C and D) IR in glioblastoma
multiforme (GBM) without (A and C) and with (B and D) levetiracetam treatment (LEV); Sections were counterstained with hematoxylin. A-D:
scale bar in D: 80 μm.
Zurolo et al. Journal of Neuroinflammation 2012, 9:280 Page 14 of 17
http://www.jneuroinflammation.com/content/9/1/280apoptosis in the tumors [17]. In contrast, other studies
suggest that the function of Kir4.1 channel is correlated
with an exit from the cell cycle (for review see [9]). Thus
the consequences of alterations in Kir4.1 expression on
the proliferation of astrocytic tumors are still unclear
and remain to be further explored. Moreover, in these
previous studies [16,17], no information concerning the
presence/absence of epilepsy or about the AED treat-
ment in epileptic patients was available and considered
in the evaluation of the correlation between Kir4.1 ex-
pression and pathologic tumor grade.
In the present study, we evaluated the expression of
Kir4.1 and IL-1β in patients in relation to the presence
or absence of epilepsy. We found a significantly lower
Kir4.1 expression in tumor tissue of patients with epi-
lepsy, which paralleled the increased expression of IL-1β.
The IL-1β-mediated downregulation of Kir4.1 expression
could represent an additional mechanism contributing
to the pro-epileptogenic effect of this cytokine. In our
study we found a significant higher IL-1β expression in
tumor tissue of patients with epilepsy and a significant
(although weak) negative correlation with the expression
levels of Kir4.1. Interestingly, a recent study shows that
minocycline treatment in the retina of diabetic rats,
increases Kir4.1 levels and this effect is associated with a
decrease of the levels of IL-1β [21].
Cytokine production, including also IL-1β, has been
previously reported in human astrocytoma cell lines and
surgical specimens of astrocytic tumors ([52-55] for re-
view see [56]). We confirmed IL-1β expression in tumorcells, of both low- and high-grade astrocytomas, in
agreement with the notion that astroglial cells represent
a main source of brain IL-1β [1,57]. Accordingly, high
expression of IL-1β has also been reported in tumor
astrocytes in ganglioglioma, which represent a well-
known cause of chronic intractable epilepsy [33]. The
expression of IL-1β in tumor astrocytes may be involved
in enhancing neuronal excitability in the peritumoral re-
gion (for reviews see [1,57]). A cytokine-mediated inhib-
ition of glutamate reuptake by astrocytes may lead to
increased extracellular glutamate concentrations [58,59].
Additionally, IL-1β has been shown to increase nitric oxide
production and cortical glutamate release [60]. Further-
more, IL-1β may also regulate gamma-aminobutyric acid
(GABA)-mediated Cl- fluxes (possibly reducing inhibitory
transmission) and molecular and functional interactions
between IL-1β and N-methyl-D-asparte (NMDA) recep-
tors have been recently reported (for reviews see [1,57]).
Substantial experimental evidence supports the proconvul-
sant role of IL-1β (for review see [1,57,61]). Thus, produc-
tion of IL-1β by tumor astrocyes may (through different
mechanisms) contribute to the epileptogenicity of glial
tumors (for review see [51]). Interestingly, the higher ex-
pression of IL-1β in tumors associated with epilepsy was
linked with increased presence of activated microglial
cells, as well as with the cytoplasmic translocation of
HMGB1, which may contribute to amplify the inflamma-
tory response via a signaling pathway involving the TLR4
[34]. Relocation of the nuclear protein to the cytoplasm
has been shown to be induced in rat [62] and human
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addition, a potential role for HMGB1 has been suggested
in promoting growth and migration of human glioblast-
oma cells [64].
Since rapid changes in IL-1β and Kir4.1 expression are
induced by seizures in experimental models (present
results; for review see [1,57,61]), we cannot exclude that
seizure activity may contribute to their level of expression.
No significant correlation was found between Kir4.1 (or IL-
1β) IR and duration of epilepsy in our cohort. However
since our study does not focus on long-term epilepsy-asso-
ciated tumors (LEATs; [65]), future investigations on a large
cohort of LEATs are necessary to address the relationship
between Kir4.1 expression and /or function and duration
and/or severity of epilepsy.
As discussed above, anti-inflammatory effects have been
reported for levetiracetam [24,25]. In particular, treatment
with this AED (but not with valproic acid) has been shown
to reduce reactive gliosis and expression levels of IL-1β in
the hippocampus and the piriform cortex in chronic epilep-
tic rats [24]. These observations prompted us to evaluate
the expression levels of both IL-1β and Kir4.1 in relation to
AED treatment, in particular the exposure to levetiracetam.
Among the patients with epilepsy who were treated with
levetiracetam, we found significantly higher expression
levels of Kir4.1, and, conversely, lower expression of IL-1β,
compared to patients who did not use this AED. These
observations, together with previous experimental findings
[24] suggest that an anti-inflammatory effect (targeting the
IL-1β system) could, at least in part, contribute to the anti-
epileptic effect of levetiracetam.
We acknowledge limitations to the interpretation of
these results, since the cohort was relatively small to as-
sess whether Kir4.1 expression is directly dependent on
the presence or absence of seizures or on tumor type.
Further quantitative analysis and in vitro electrophysio-
logical studies are needed to confirm these findings and
to establish their functional significance. However, this
report underscores the complexity of Kir4.1 alterations
in astrocytes and astrocytic tumor cells, and the poten-
tial contribution of the local inflammatory environment,
involving in particular the pro-inflammatory cytokine
IL-1β, in regulating the expression of Kir4.1 in epilepsy-
associated lesions. Whether this mechanism could play a
role in other neurological disorders (multiple sclerosis,
neurodegenerative disorders) characterized by high
levels of IL-1β and dysfunction of Kir4.1 [49,66,67]
deserves further investigation.
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